University Hospital of Bellvitge

We collaborate with many different partners to support and promote ALS research. For example, our center works together with INP (Institute of Neuropathology of HUB) and IDIBELL (Institute of Biomedical Research of Bellvitge), Biobank HUB-ICO-Idibell (DNA and other samples of ALS patients), and CIBERNED (Network Centre for the Study of Neurodegenerative Diseases; National Institute of Health Carlos III).

The Miquel Valls Foundation is a non-profit organization that aims to improve the quality of life of people suffering from ALS and offers support to their families. The foundation also promotes research in ALS.

Contact
Location
Bellvitge University Hospital, Carrer de la Feixa Llarga, L'Hospitalet de Llobregat, Spain

Specialists

Mónica Povedano

Head of department of neurophysiology and Coordinator of ALS unit

Mónica Povedano is an expert in neuromuscular disease and obtained her medical […]

Mónica Povedano
Current trials
Recruiting
Phase iii

ALXN1210-ALS-308 trial

Industry trial
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Read more
Recruiting
Phase iii

VALOR study

Industry trial
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
Read more
In preparation
Phase iii

The Lighthouse 2 trial

Investigator initiated trial
The Lighthouse 2 study is a phase 3 clinical trial in which we will investigate the efficacy of the drug Triumeq.
Read more
In preparation
Phase iii

MAGNET

Platform trial
MAGNET is an innovative clinical platform trial in which multiple treatments for ALS are investigated simultaneously.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more